Sachin Phakey

Sachin Phakey

Auto-generated profile, based on publicly available information

Sachin Phakey

The Royal Melbourne Hospital

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Australian Journal of General Practice
Verified
Journal Article
Closed access
SPSachin Phakey
Sachin Phakey
ASAngeline Shen
Angeline Shen
This retrospective population-based study examines semaglutide and dulaglutide prescriptions for type 2 diabetes supplied via the Pharmaceutical Benefits Scheme from January 2021 to September 2022.

6 October 2023 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
SPSachin Phakey
Sachin Phakey
JLJasmine Lichtenstein
Jasmine Lichtenstein
LLLyndell Lim
Lyndell Lim

4 October 2024 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
SPSachin Phakey
Sachin Phakey
PCPatricia T. Campbell
Patricia T. Campbell
KGKatherine Gibney
Katherine Gibney
In the last 10–15 years, there has been a global resurgence of scarlet fever, an infection historically associated with significant morbidity and mortality. It is unknown whether scarlet fever incidence has increased in Australia. We aimed to examine the incidence, predictors and severity of scarlet fever in the state of Victoria, Australia from 2007 to 2017, analyzing scarlet fever emergency department (ED) presentations, hospitalizations and deaths. Of the 1 578 scarlet fever cases during the study period, most occurred in children aged <10 years (1 344, 85%), in males (882, 56%), and during winter and spring months (918, 57%). There were no deaths with scarlet fever, however, 374 cases (24%) were admitted to hospital. The annual incidence of scarlet fever was stable during the study period (mean, 2.5; range, 1.9–3.1 cases per 100 000). Annual incidence was highest in children aged <5 years (19.3 per 100 000), and was 21% higher in males than females, adjusting for age and year (incidence rate ratio, 1.21, 95%CI 1.09–1.34). Whilst scarlet fever ED presentations and hospitalizations were stable in Victoria from 2007 to 2017, the recent identification of a Streptococcus pyogenes variant in Australia associated with epidemic scarlet fever overseas highlights the risk of future outbreaks.

1 June 2021 in Psychiatric Genetics
Verified
Journal Article
Closed access
SPSachin Phakey
Sachin Phakey
MWMark Walterfang
Mark Walterfang

10 January 2023 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
SPSachin Phakey
Sachin Phakey
SRSophie L. Rogers
Sophie L. Rogers
AHAnthony J. Hall
Anthony J. Hall
LLLyndell Lim
Lyndell Lim
Introduction Zostavax, the live-attenuated vaccine used to prevent herpes zoster (HZ), has been available to individuals aged 70 and 71–79 years (phased catch-up) via Australia’s National Immunisation Program (NIP) since 2016. There are limited data characterising the incidence of HZ at the level of the Australian population. National prescription data for antivirals used to treat HZ may be used as a proxy for HZ incidence. We aimed to examine trends in antiviral prescriptions supplied for the treatment of HZ in Australia pre- and post-2016, and to assess whether Zostavax’s inclusion on the NIP correlated with a reduction in HZ antiviral prescription rates. Methods Using the Australian Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme prescribing data, we analysed antiviral prescriptions supplied for the treatment of HZ Australia-wide between 1994 and 2019. Annual prescription rates were calculated, and trends and changes in HZ antiviral use were explored descriptively and using Poisson models. Results HZ antiviral prescription rates increased 2.6-fold (160%) between 1995 and 2015 [25.4 (95% CI 25.2, 25.6) and 65.3 (95% CI 64.9, 65.6) prescriptions per 10,000 people, respectively], and then decreased 0.45-fold (55%) between 2016 and 2018 [60.9 (95% CI 60.6, 61.2) and 27.5 (95% CI 27.3, 27.9) prescriptions per 10,000 people, respectively]. The prescription rate for the antiviral famciclovir restricted specifically for treating HZ in immunocompromised individuals increased 8.5-fold (750%) between 2006 (year first listed) and 2019 [0.3 (95% CI 0.3, 0.3) and 2.5 (95% CI 2.4, 2.6) prescriptions per 10,000 people, respectively]. Conclusion The introduction of the live-attenuated HZ vaccine on Australia’s formal national vaccination program was associated with a reduction in HZ antiviral prescription rates within the Australian population. The data suggest that the introduction of Shingrix, the non-live subunit zoster vaccine, may also be associated with a similar reduction in HZ antiviral prescriptions used to treat the immunocompromised, as well as the general population, given its accepted greater efficacy over Zostavax.

15 February 2023 in Ophthalmic Epidemiology
Verified
Journal Article
Open access
SPSachin Phakey
Sachin Phakey
AHAnthony J Hall
Anthony J Hall
LLLyndell Lim
Lyndell Lim
We investigate the impact of COVID-19 and lockdowns on anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD) in Victoria (Australian s...